CUE
Cue Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.44
−0.83%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.0x
Market Cap
$199.34M
MomentumView details →
1D Return
−0.83%
YTD Return
+199.36%
RSI (14)
49.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.0x
Market Cap
$199.34M
RSI (14)
49.3
MomentumView details →
1D Return
−0.83%
YTD Return
+199.36%
SummaryUpdated Jun 1, 2026
Cue Biopharma, Inc. (NASDAQ:CUE) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Cambridge, Massachusetts. Originally incorporated as Imagen Biopharma, Inc., the company changed its name to Cue Biopharma in October 2016 and went public in January 2018. The company focuses on developing innovative biologic drugs that selectively modulate the human immune system to treat cancers, chronic infectious diseases, and autoimmune disorders through its proprietary Immuno-STAT platform technology.
Similar companies
Latest newsMore news →
Cue Biopharma announced a private placement of securities to raise approximately $50 million in gross proceeds.22d agoCue Biopharma announced the appointment of James M. Ahlers as Chief Financial Officer on August 3, 2026.33d agoCue Biopharma announced a private placement of common stock and pre-funded warrants to accredited investors for gross proceeds of approximately $50.0 million.57d ago